Wedbush Research Analysts Lower Earnings Estimates for APGE

Apogee Therapeutics, Inc. (NASDAQ:APGE) – Analysts at Wedbush dropped their Q1 2025 earnings per share (EPS) estimates for shares of Apogee Therapeutics in a research note issued to investors on Monday, March 3rd. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($1.24) for the quarter, down from their previous forecast of ($0.99). Wedbush currently has a “Outperform” rating and a $90.00 price target on the stock. The consensus estimate for Apogee Therapeutics’ current full-year earnings is ($3.09) per share. Wedbush also issued estimates for Apogee Therapeutics’ Q2 2025 earnings at ($1.26) EPS, Q3 2025 earnings at ($1.21) EPS, Q4 2025 earnings at ($1.21) EPS, FY2025 earnings at ($4.92) EPS, FY2026 earnings at ($5.07) EPS, FY2027 earnings at ($5.56) EPS and FY2028 earnings at ($7.00) EPS.

Apogee Therapeutics (NASDAQ:APGE) last released its earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.25).

APGE has been the topic of several other research reports. Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Canaccord Genuity Group began coverage on Apogee Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $89.00 target price on the stock. Finally, Canaccord Genuity Group began coverage on Apogee Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $89.00 target price on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Apogee Therapeutics has an average rating of “Buy” and an average price target of $88.83.

Apogee Therapeutics Price Performance

Shares of Apogee Therapeutics stock opened at $31.43 on Thursday. Apogee Therapeutics has a one year low of $29.10 and a one year high of $72.29. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -12.99 and a beta of 2.46. The stock’s 50-day moving average is $39.67 and its 200-day moving average is $47.21.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new stake in Apogee Therapeutics during the 4th quarter worth about $43,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Apogee Therapeutics during the 3rd quarter valued at about $71,000. Wexford Capital LP acquired a new position in Apogee Therapeutics during the 3rd quarter valued at about $230,000. Optimize Financial Inc acquired a new position in Apogee Therapeutics during the 4th quarter valued at about $203,000. Finally, Aigen Investment Management LP bought a new position in shares of Apogee Therapeutics during the 4th quarter worth approximately $216,000. 79.04% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Mark C. Mckenna purchased 20,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $49.54 per share, for a total transaction of $990,800.00. Following the purchase, the director now owns 20,000 shares of the company’s stock, valued at approximately $990,800. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael Thomas Henderson sold 15,000 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $40.58, for a total value of $608,700.00. Following the completion of the transaction, the chief executive officer now owns 1,302,987 shares of the company’s stock, valued at $52,875,212.46. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 42,145 shares of company stock worth $1,897,799 over the last three months. Insiders own 36.10% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.